New York, US – Dec 18, 2019 – World Health Organization (WHO) survey shows that, 125 million people globally suffer from a serious auto-immune disease called Psoriasis. 70% of psoriasis patients face social discrimination.
Psoriasis is a severe, chronic, non-communicable disease (NCD) that dramatically reduces the quality of life of affected individuals, and takes a high mental, emotional, social, and economic toll on them.
Treatment can reduce signs and symptoms of psoriasis, which usually makes a person feel better. With treatment, some people see their skin completely clear. Effective treatment can significantly improve quality of life.
Apremilast (Aprezo) was approved in the US in 2014 for treatment of adults with active psoriatic arthritis and moderate-to-severe plaque psoriasis. But otezla cost per month is more than 3000USD per month, most of people cannot afford the apremilast cost.
According to the Indian Journal of Dermatology, Venereology and Leprology, about 33 million people in India suffer from psoriasis.
From 2018, the lucky India psoriasis patients can get the generic Apremilast Rs 6,000 per month. Aprezo (Apremilast 30mg) are relatively much cheaper than otezla price. “Safety profile of apremilast and xeljanz generic are established through clinical trials and post marketing survey abroad but we will get more clarity once it starts getting prescribed in India. We will also have to monitor its efficacy,” Dr. Sushil Tahiliani, a dermatologist in Mumbai, said.
Many overseas patients who cannot afford the brand medicine come to India or buy the generic medicine. They fight for social discrimination and also searching for new hope.
While the treatments are very important to fight psoriasis, it is also essential to be empathetic towards patients and encourage them to feel confident.